Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$151.73 USD
-1.38 (-0.90%)
Updated Jul 5, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 661 - 667 ( 667 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Increasing Price Target to $26 - Eteplirsen Shows Statistically Significant Clinical Benefit in 6-Minute Walk
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Unprecedented Benefit in DMD Patients Reported By Use of Eteplirsen in Study 202
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
100% Survival Reported in a Non-human Primate Study of AVI-7288 for Marburg Virus
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M